1447 related articles for article (PubMed ID: 33168456)
1. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
Indu P; Rameshkumar MR; Arunagirinathan N; Al-Dhabi NA; Valan Arasu M; Ignacimuthu S
J Infect Public Health; 2020 Dec; 13(12):1856-1861. PubMed ID: 33168456
[TBL] [Abstract][Full Text] [Related]
2. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
3. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
4. Repurposing of FDA-approved drugs as potential inhibitors of the SARS-CoV-2 main protease: Molecular insights into improved therapeutic discovery.
Ray AK; Sen Gupta PS; Panda SK; Biswal S; Bhattacharya U; Rana MK
Comput Biol Med; 2022 Mar; 142():105183. PubMed ID: 34986429
[TBL] [Abstract][Full Text] [Related]
5. Computational drug repurposing study of antiviral drugs against main protease, RNA polymerase, and spike proteins of SARS-CoV-2 using molecular docking method.
Jalalvand A; Khatouni SB; Najafi ZB; Fatahinia F; Ismailzadeh N; Farahmand B
J Basic Clin Physiol Pharmacol; 2021 Jul; 33(1):85-95. PubMed ID: 34265888
[TBL] [Abstract][Full Text] [Related]
6. Repurposing immune boosting and anti-viral efficacy of
Dinata R; Nisa N; Arati C; Rasmita B; Uditraj C; Siddhartha R; Bhanushree B; Saeed-Ahmed L; Manikandan B; Bidanchi RM; Abinash G; Pori B; Khushboo M; Roy VK; Gurusubramanian G
J Biomol Struct Dyn; 2024; 42(1):43-81. PubMed ID: 37021347
[TBL] [Abstract][Full Text] [Related]
7. Computational selection of flavonoid compounds as inhibitors against SARS-CoV-2 main protease, RNA-dependent RNA polymerase and spike proteins: A molecular docking study.
Rameshkumar MR; Indu P; Arunagirinathan N; Venkatadri B; El-Serehy HA; Ahmad A
Saudi J Biol Sci; 2021 Jan; 28(1):448-458. PubMed ID: 33110386
[TBL] [Abstract][Full Text] [Related]
8. Targeting SARS-CoV-2 RNA-dependent RNA polymerase: An
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
F1000Res; 2020; 9():1166. PubMed ID: 33204411
[No Abstract] [Full Text] [Related]
9. Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.
Rai H; Barik A; Singh YP; Suresh A; Singh L; Singh G; Nayak UY; Dubey VK; Modi G
Mol Divers; 2021 Aug; 25(3):1905-1927. PubMed ID: 33582935
[TBL] [Abstract][Full Text] [Related]
10. Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review.
Mohamed K; Yazdanpanah N; Saghazadeh A; Rezaei N
Bioorg Chem; 2021 Jan; 106():104490. PubMed ID: 33261845
[TBL] [Abstract][Full Text] [Related]
11. Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19.
Talluri S
Comb Chem High Throughput Screen; 2021; 24(5):716-728. PubMed ID: 32798373
[TBL] [Abstract][Full Text] [Related]
12. Integrated bioinformatics-cheminformatics approach toward locating pseudo-potential antiviral marine alkaloids against SARS-CoV-2-Mpro.
Swain SS; Singh SR; Sahoo A; Panda PK; Hussain T; Pati S
Proteins; 2022 Sep; 90(9):1617-1633. PubMed ID: 35384056
[TBL] [Abstract][Full Text] [Related]
13. Repurposing of potential antiviral drugs against RNA-dependent RNA polymerase of SARS-CoV-2 by computational approach.
Gangadharan S; Ambrose JM; Rajajagadeesan A; Kullappan M; Patil S; Gandhamaneni SH; Veeraraghavan VP; Nakkella AK; Agarwal A; Jayaraman S; Surapaneni KM
J Infect Public Health; 2022 Nov; 15(11):1180-1191. PubMed ID: 36240528
[TBL] [Abstract][Full Text] [Related]
14. In Silico Identification of a Potent Arsenic Based Approved Drug Darinaparsin against SARS-CoV-2: Inhibitor of RNA Dependent RNA polymerase (RdRp) and Essential Proteases.
Chowdhury T; Roymahapatra G; Mandal SM
Infect Disord Drug Targets; 2021; 21(4):608-618. PubMed ID: 32718300
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
[TBL] [Abstract][Full Text] [Related]
16. In silico prediction of SARS-CoV-2 main protease and polymerase inhibitors: 3D-Pharmacophore modelling.
Mosayebnia M; Hajiagha Bozorgi A; Rezaeianpour M; Kobarfard F
J Biomol Struct Dyn; 2022 Sep; 40(14):6569-6586. PubMed ID: 33599180
[TBL] [Abstract][Full Text] [Related]
17. Repositioning Therapeutics for SARS-CoV-2: Virtual Screening of Plant-based Anti-HIV Compounds as Possible Inhibitors against COVID-19 Viral RdRp.
Murali M; Gowtham HG; Ansari MA; Alomary MN; Alghamdi S; Almehmadi M; Singh SB; Shilpa N; Aiyaz M; Kalegowda N; Ledesma AE; Amruthesh KN
Curr Pharm Des; 2022; 28(12):969-980. PubMed ID: 35796443
[TBL] [Abstract][Full Text] [Related]
18. Potential Candidates against COVID-19 Targeting RNA-Dependent RNA Polymerase: A Comprehensive Review.
Agrawal N; Goyal A
Curr Pharm Biotechnol; 2022; 23(3):396-419. PubMed ID: 33882805
[TBL] [Abstract][Full Text] [Related]
19. Computational Screening Using a Combination of Ligand-Based Machine Learning and Molecular Docking Methods for the Repurposing of Antivirals Targeting the SARS-CoV-2 Main Protease.
Yuda GPWC; Hanif N; Hermawan A
Daru; 2024 Jun; 32(1):47-65. PubMed ID: 37907683
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Binding Affinity of Anti-Viral Drugs against Main Protease of SARS-CoV-2 Through a Molecular Docking Study.
Mondal M; Sarkar C; Jamaddar S; Khalipha ABR; Islam MT; Mahafzah A; Mubarak MS
Infect Disord Drug Targets; 2021; 21(7):e160921188777. PubMed ID: 33292147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
